Type 2 Diabetes
Auxilium reports results from phase IV trial of Testim in diabetes patients
Published in Obesity and Diabetes Week, July 10th, 2006
This double-blind, placebo-controlled study of 204 patients showed that patients treated with Testim experienced a statistically significant improvement in serum testosterone levels (p less than or equal to 0.001) compared to those receiving placebo. Patients in the Testim treatment group also experienced a statistically significant increase in lean body mass (muscle mass) (p=0.026) and decrease in fat mass (p less than or equal to 0.001) compared to the control group, confirming...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Therapy
Candesartan protects beta-cell function in diabetes mouse model - Diabetes Therapy
Estradiol improves glucose tolerance and insulin sensitivity in ob/ob mice - Obesity & Diabetes Pathogenesis
Fat and glucose regulate pyruvate dehydrogenase kinase mRNA in pancreatic islets - Obesity Epidemiology
Prenatal nutrition shapes obesity risk through changes in leptin sensitivity - Obesity Pathogenesis
Inhibin beta B expression is high in adipocytes and may correlate to metabolic disease risk - Adenocarcinomas
High body mass index increases adenocarcinoma risk in the esophagus or gastric cardia - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
